Portal Biotech
Founded 2021 · 70 employees on LinkedIn · 2 known investors
Portal Biotech develops bench-top instruments that use nanopore biosensors coupled with machine learning to detect, sequence, and characterise single protein and metabolite molecules, revealing modifications, mutations, and isoforms. The technology, spun out of the Maglia Lab at the University of Groningen, serves academic research, biopharmaceutical, biotechnology, and industrial labs for proteomic and metabolomic analysis.
Investors · 2
Funding
SEC filings, press & company announcements$35M disclosed across 1 of 2 rounds · 2025
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Portal Biotech do?
- Portal Biotech develops bench-top instruments that use nanopore biosensors coupled with machine learning to detect, sequence, and characterise single protein and metabolite molecules, revealing modifications, mutations, and isoforms. The technology, spun out of the Maglia Lab at the University of Groningen, serves academic research, biopharmaceutical, biotechnology, and industrial labs for proteomic and metabolomic analysis.
- Who are Portal Biotech's investors?
- Portal Biotech's investors include Pillar VC, Earlybird Venture Capital.
- How much funding has Portal Biotech raised?
- Portal Biotech has disclosed $35M raised across 1 of its 2 known rounds.